LOGIN
Denosumab increases bone mass but does not reduce fracture risk compared to alendronate
May 2013
Denosumab increases bone mass but does not reduce fracture risk compared to alendronate
Study Type:Meta-analysis/Systematic Review
OE Level Evidence:1
Journal Level of Evidence:N/A
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis
Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
4 randomised control trials were included in this meta-analysis, to compare the effectiveness of 60mg Denosumab subcutaneously per 6 months (Den) to 70mg Alendronate orally per week (Aln) in the treatment of osteoporosis in postmenopausal women. A total of 1952 women were identified that were followed-up for one year. The primary outcomes were the incidence of clinical fractures and bone mineral d...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.